ATE318896T1 - Rekombinante rna-replikase von hepatitis-c-virus - Google Patents

Rekombinante rna-replikase von hepatitis-c-virus

Info

Publication number
ATE318896T1
ATE318896T1 AT96933178T AT96933178T ATE318896T1 AT E318896 T1 ATE318896 T1 AT E318896T1 AT 96933178 T AT96933178 T AT 96933178T AT 96933178 T AT96933178 T AT 96933178T AT E318896 T1 ATE318896 T1 AT E318896T1
Authority
AT
Austria
Prior art keywords
hcv
rdrp
hepatitis
virus
vitro
Prior art date
Application number
AT96933178T
Other languages
English (en)
Inventor
Curt H Hagedorn
Reinoldus H Al
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE318896T1 publication Critical patent/ATE318896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96933178T 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus ATE318896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27

Publications (1)

Publication Number Publication Date
ATE318896T1 true ATE318896T1 (de) 2006-03-15

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933178T ATE318896T1 (de) 1995-09-27 1996-09-27 Rekombinante rna-replikase von hepatitis-c-virus

Country Status (8)

Country Link
US (2) US5981247A (de)
EP (1) EP0859833B1 (de)
JP (1) JP4191797B2 (de)
AT (1) ATE318896T1 (de)
AU (1) AU719122B2 (de)
CA (1) CA2233309A1 (de)
DE (1) DE69635864T2 (de)
WO (1) WO1997012033A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) * 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
AU1905399A (en) * 1997-12-11 1999-06-28 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
WO1999051781A1 (en) * 1998-04-02 1999-10-14 Viropharma Incorporated Hepatitis c virus ns5b compositions and methods of use thereof
CA2331920A1 (en) * 1998-06-24 1999-12-29 International Reagent Corporation Hcv-derived rna polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
WO2001077371A1 (fr) * 2000-04-07 2001-10-18 Shionogi & Co., Ltd. Procede de dosage de preincubation
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
IL156457A0 (en) * 2001-01-31 2004-01-04 Bristol Myers Squibb Pharma Co An in-vitro method for genomic replication
JP4338402B2 (ja) * 2001-05-22 2009-10-07 ユニバーシティ オブ シカゴ Ｎ４ウイルス一本鎖ｄｎａ依存的ｒｎａポリメラーゼ
AU2002325755A1 (en) * 2001-09-18 2003-04-01 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
US20030104445A1 (en) * 2001-09-25 2003-06-05 Hayes Robert J. RNA dependent RNA polymerase mediated protein evolution
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
AU2002360394A1 (en) * 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
US7329732B2 (en) * 2004-01-09 2008-02-12 Merck & Co., Inc. HCV RNA-dependent RNA polymerase
US7414031B2 (en) 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
HRP20070435A9 (en) 2005-02-28 2008-09-30 Genelabs Technologies Tricyclic-nucleoside compounds for treating viral infections
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
KR20110065440A (ko) 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
NZ599373A (en) 2009-11-14 2013-04-26 Hoffmann La Roche Biomarkers for predicting rapid response to hcv treatment
AU2010326781A1 (en) 2009-12-02 2012-04-19 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to HCV treatment
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
EA201300160A1 (ru) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
WO1997012033A1 (en) 1997-04-03
US6248589B1 (en) 2001-06-19
EP0859833A1 (de) 1998-08-26
AU719122B2 (en) 2000-05-04
AU7200796A (en) 1997-04-17
EP0859833B1 (de) 2006-03-01
DE69635864T2 (de) 2006-10-26
DE69635864D1 (de) 2006-04-27
JP4191797B2 (ja) 2008-12-03
JPH11514862A (ja) 1999-12-21
US5981247A (en) 1999-11-09
EP0859833A4 (de) 2001-03-28
CA2233309A1 (en) 1997-04-03

Similar Documents

Publication Publication Date Title
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
Borman et al. elF4G and its proteolytic cleavage products: effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs.
Kessler et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase
Wirth et al. How a single Sindbis virus mRNA directs the synthesis of one soluble protein and two integral membrane glycoproteins
Denkewalter et al. Total synthesis of an enzyme. I. Objective and strategy
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
WO2021261577A1 (ja) 改変された遺伝暗号表を有する翻訳系
Barth et al. The oligomerization reaction of the Semliki Forest virus membrane protein subunits.
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
GB9722320D0 (en) Human cell cycle checkpoint proteins
GB9810999D0 (en) Materials and methods relating to the expression of genes
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
Hansen et al. Presence of the cap-binding protein in initiation factor preparations from poliovirus-infected HeLa cells
Tanese et al. Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase
Robert et al. Interactions with tRNALys induce important structural changes in human immunodeficiency virus reverse transcriptase
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
AP2368A (en) Novel expression vectors and uses thereof.
Skoging-Nyberg et al. MXI motif of Semliki Forest virus capsid protein affects nucleocapsid assembly
GR3007909T3 (de)
Borovsky et al. Juvenile hormone affects the splicing of Culex quinquefasciatus early trypsin messenger RNA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties